An Open-Label, Multicenter, Phase 1 Study With Expansion Cohorts of Ramucirumab or Necitumumab in Combination With Osimertinib in Patients With Advanced T790M-Positive EGFR-Mutant Non-Small Cell Lung Cancer After Progression on First-Line EGFR TKI Therapy

Trial Profile

An Open-Label, Multicenter, Phase 1 Study With Expansion Cohorts of Ramucirumab or Necitumumab in Combination With Osimertinib in Patients With Advanced T790M-Positive EGFR-Mutant Non-Small Cell Lung Cancer After Progression on First-Line EGFR TKI Therapy

Recruiting
Phase of Trial: Phase I

Latest Information Update: 23 Oct 2017

At a glance

  • Drugs Necitumumab (Primary) ; Osimertinib (Primary) ; Ramucirumab (Primary)
  • Indications Non-small cell lung cancer
  • Focus Adverse reactions
  • Sponsors Eli Lilly
  • Most Recent Events

    • 18 Oct 2017 According to results presented at the 18th World Conference on Lung Cancer, as of data cutoff on 09-May-2017, 7 patients were treated in the completed dose-finding portion and expansion cohort A of Ramucirumab + Osimertinib is fully enrolled with 22 patients.
    • 18 Oct 2017 Results assessing the safety of ramucirumab or necitumumab in combination with osimertinib in participants with non-small cell lung cancer (NSCLC), were presented at the 18th World Conference on Lung Cancer.
    • 22 Jun 2017 Planned End Date changed from 1 Apr 2020 to 1 May 2019.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top